1. Home /
    2. Altai Protocol Library /
  2. New Indication: Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

New Indication: Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Study:
  • Open-label, phase 2 study
  • Treatment naïve resectable sage IIIB-IVC metastatic melanoma (cutaneous, acral, or mucosal)
  • Pembrolizumab: Neoadjuvant x 3 + Adjuvant x 15 doses (n=154) vs. Adjuvant x 18 doses (n=159)
Efficacy:
  • 2-year EFS: 72% vs. 49%, p=0.004
Safety:
  • Grade≥ 3 AEs: ALT increased (1% vs. NA), AST increased (1% vs. NA)

N Engl J Med 2023; 388:813-823

Patel P. Sabna et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

http://doi.org/10.1056/NEJMoa2211437

Reviewed by Elvin CHALABİYEV, MD on APR 17, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More